TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02621931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab was provided as a sterile, unpreserved, aqueous solution for injection, 225 mg/1.5 mL pre-filled syringe for single-use administration. The 675 mg dose was given as 3 injections; doses of 225 mg were given as a single injection. Study drug was administered at the clinical site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab was provided as a sterile, unpreserved, aqueous solution for injection, 225 mg/1.5 mL pre-filled syringe for single-use administration. The 675 mg dose was given as 3 injections; doses of 225 mg were given as a single injection. Study drug was administered at the clinical site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.
Study: NCT01353352

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical decision rule - clearing the c-spine
Description: The goal of phase IV of the Canadian C-Spine Rule project is to evaluate the safety and potential impact of an active strategy to empower ED triage nurses to evaluate and clear the c-spine of very low-risk trauma patients.
Study: NCT03877094

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nature virtual reality video
Description: the patient will receive a head-set dispositive to watch a nature virtual reality video during the whole procedure of breast biopsy
Study: NCT00536133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: 5 ml of syrup containing zinc gluconate equivalent to 10 mg of elemental zinc per day for 60 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 5 ml of syrup, identical in taste, color and consistency to the syrup given to zinc group, but containing no zinc
Study: NCT03801785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pacifier
Description: The pacifiers used in this clinical trial have the same shape and material. They are produced by Artsana S.P.A. for soothing children. As such, the FDA has no jurisdictions over pacifiers (US FDA regulations May 15, 2012 https://www.fdaimports.com/blog/pacifiers-fda-change-abi-system/) because they are not medical devices intended for teething.
Study: NCT02427126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Apixaban is an oral anticoagulant currently approved for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, for the treatment of deep vein thrombosis and pulmonary embolism, and for the prophylaxis of systemic embolism after orthopedic surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Acetylic Salicylic Acid 100mg o.d.; 12 Months
Study: NCT02541552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Description: Varying volume according to motor response of previous subject
Study: NCT01847703

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic surgery
Description: Minimal invasive surgery performed with daVinci robotic system

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal surgery
Description: Current gold standard
Study: NCT02792166

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BPD-DS
Description: Biliopancreatic Diversion with Duodenal Switch
Study: NCT03860272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: An Fc-engineered anti-CTLA-4 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: An Fc-engineered anti-CTLA-4 monoclonal antibody
Study: NCT02792166

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SADI-S
Description: Single Anastomosis Duodeno-ileal Bypass with Sleeve Gastrectomy
Study: NCT01835457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide
Description: LPS is used to elicit an inflammatory response in all subjects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipopolysaccharide
Description: LPS is used to elicit an inflammatory response in all subjects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concentration/meditation
Description: A self-taught concentration/meditation technique that Mr Wim Hof developed himself, characterized by cycles consisting of a few minutes of hyperventilation followed by breath holding for up to 1-2 minutes and deep concentration (mindset).
Study: NCT01039051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Lifestyle Intervention in Chinese Postpartum Women
Description: For individual postpartum woman, we will set antepartum participatory training courses, provide specially prepared brochures and supporting VCD, set up a specialized counseling hotline and give individual bedside guidance after birth. For their family members, we will invite every postpartum woman's husband and mother to take part in workshops or seminars, making them know some basic knowledge of postpartum care, and persuading them to promote adoption of the diet and lifestyle we advocated by the postpartum woman. For community environment, we will put up posters about basic knowledge of postpartum care in the community bulletin boards for general population educating and mobilize community leaders and heads from and maternal and child health centers for maximum support.
Study: NCT01499004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib (CP-690,550) modified-release formulation A
Description: A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib (CP-690,550) modified-release formulation B1
Description: A single dose of 22 mg tofacitinib (CP-690,550) MR-B1 formulation administered with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib (CP-690,550) modified-release formulation A
Description: A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered without food
Study: NCT00696709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: V212
Description: 0.65 mL subcutaneous injection of heat-treated Varicella zoster virus (VZV) vaccine or alternative inactivation method VZV vaccine A, B, C; 4-dose regimen administered \~30 days apart

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo; 4-dose regimen administered \~30 days apart.
Study: NCT01499004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib (CP-690,550) modified-release formulation B1
Description: A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B1 administered without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib (CP-690,550) modified-release formulation B2
Description: A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B2 administered without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib (CP-690,550) immediate-release formulation
Description: A single dose of 10 mg tofacitinib (CP-690,550) immediate-release formulation administered without food
Study: NCT00955357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Oral Lacosamide:~Subjects Titration Phase (6 Weeks):~Week 1 - 50 mg tablet Twice daily (bid); Week 2 - 100 mg tablet bid; Week 3 - 150 mg tablet bid; Week 4 - 200 mg tablet bid; Week 5 - 200 mg tablet bid; Week 6 - 150 mg tablet bid OR Week 6 - 200 mg tablet bid~Maintenance Phase (24 Weeks):~200 mg tablet bid OR 150 mg tablet bid~Taper Phase (1 - 3 Weeks):~50 mg tablet bid for 1 week OR 100 mg tablet bid for 1 week OR 150 mg tablet bid for 1 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Oral Lacosamide:~Subjects Titration Phase (6 Weeks):~Week 1 - 50 mg tablet Twice daily (bid); Week 2 - 100 mg tablet bid; Week 3 - 150 mg tablet bid; Week 4 - 200 mg tablet bid; Week 5 - 200 mg tablet bid; Week 6 - 150 mg tablet bid OR Week 6 - 200 mg tablet bid~Maintenance Phase (24 Weeks):~200 mg tablet bid OR 150 mg tablet bid~Taper Phase (1 - 3 Weeks):~50 mg tablet bid for 1 week OR 100 mg tablet bid for 1 week OR 150 mg tablet bid for 1 week
Study: NCT03199222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prosthetic smart socket technology with patient prompting
Description: The smart socket technology will send feedback to the user's smartphone with suggestions including the removal or application of prosthetic socks over the residual limb or other volume management strategies to improve fit and comfort.
Study: NCT00609687

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Diagnostic Vitrectomy
Description: Three-port, 20-gauge pars plana vitrectomy instrumentation was utilized. An infusion line was inserted into one sclerotomy and secured to the globe. A second sclerotomy was made, and a fiberoptic light pipe was immediately inserted to minimize vitreous egress. A third sclerotomy was created, and the vitreous cutter was inserted. To obtain an undiluted vitreous sample, the vitreous was cut mechanically with the vitreous cutter, while the assistant surgeon simultaneously manually aspirated the vitreous. After sufficient undiluted sample was obtained, infusion fluid was allowed to enter the eye and a diluted vitreous sample was obtained in a similar manner. The samples were personally carried to the clinical laboratories by the operating surgeon.~Vitreous fluid analysis was guided by clinical suspicion based on the pre-operative differential diagnosis and the intraoperative posterior segment appearance.
Study: NCT03621605

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VIB9600
Description: Part 1 (SAD): IV infusion (30, 100, 200, 300 or 1000 mg) or SC injection (300 mg) on Day 1.~Part 2 (MAD): IV infusion (100 and 300 mg) every 2 weeks for 4 weeks (3 doses total; Days 1, 15 and 29).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo administered by slow IV infusion or SC injection.
Study: NCT01505296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drug
Description: propafenone, flecainide, sotalol, dofetilide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Description: Complete PVI
Study: NCT01421563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anplag
Description: Sarpogrelate HCl 300mg once a day or 100mg three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anplag
Description: Sarpogrelate HCl 300mg once a day or 100mg three times a day
Study: NCT03860272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: An Fc-engineered anti-CTLA-4 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: A fully human monoclonal anti-PD-1 antibody
Study: NCT04857268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearable continuous ECG monitoring patch, ATP-C120
Description: ATP-C120 is a novel, single-lead ECG monitoring device which can continuously monitor the ECG signal as long as 14 days (11 days if the device is connected to the smartphone via Bluetooth) when attached to skin adjacent to the heart of patients. It weighs about 8.3 g, with a size of 84 × 39 × 8.3 mm.~When the device is attached to the patient, several predefined methods were utilized to prevent the occurrence of noise or signal loss. First, the skin was cleansed and disinfected using a 70% ethanol solution. Skin hair was removed if needed. Then the protection film was removed from the patient-side surface of the device. The device is placed at the left 3rd intercostal space 45 degrees tilted toward the inside.
Study: NCT04039399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic Conditioning
Description: Ischemic conditioning is a well-defined, non-invasive procedure which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 225 mmHg to occlude blood flow to the limb for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. In our study, participants will receive one session of the intervention (45 minutes total).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Ischemic Conditioning
Description: There will also be an IC Sham group which is identical to the IC intervention, except the cuff is only inflated to 10 mmHg, which is a high enough pressure to perceive cuff tightness but not high enough to have any physiological effects.
Study: NCT01214772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heparin
Description: 5000 IU subcutaneously in the day of embryo transfer until 6 week after delivery
Study: NCT03597568

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Resveratrol
Description: Oral supplementation for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Oral supplementation for 6 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral supplementation for 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral supplementation for 6 weeks
Study: NCT06133400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaire about socio-demographical status, health status and lifestyle habits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical measurements
Description: Measurement of height, weight, waist circumference, blood pressure and skin pigmentation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological samples
Description: Collect venous blood, saliva and stool samples
Study: NCT01808209

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stenfilcon A
Description: Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
Study: NCT02460718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENCOURAGE Study
Description: This intervention tested the effects of a peer coaching program plus brief diabetes education versus brief diabetes education alone on diabetes outcomes.
Study: NCT03481049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual CM
Description: Behavioral reinforcement for alcohol abstinence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Magnitude CM
Description: Behavioral reinforcement for alcohol abstinence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shaping CM
Description: Behavioral reinforcement for alcohol abstinence
Study: NCT05148377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liquaemin
Description: The standardized dose for the study was 150UI / kg heparin. It was administered directly through the dialysis equipment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heptar
Description: The standardized dose for the study was 150UI / kg heparin. It was administered directly through the dialysis equipment.
Study: NCT03599648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BPT-M
Description: Participants randomized to the BPT-M condition receive the Mindfulness-Based Stress Reduction (MBSR) intervention, followed by Behavioral Parent Training (BPT). The MBSR module includes six weekly 2.5 hour group sessions, 30-45 minutes of daily home practice guided by audio CDs, and an MBSR parent workbook. In the sessions, participants practice formal mindfulness exercises, and are provided instruction on stress physiology and using mindfulness for coping with stress in everyday life.~The BPT component of the intervention includes 10 weekly sessions lasting 2.5 hours. Each session is structured around videotape vignettes and uses discussion, role-playing, modeling, and feedback to foster mastery of the material. Parents are given weekly homework assignments and practice their skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BPT-E
Description: Participants randomized to the BPT-E condition will received 6 weeks of a psychoeducation program followed by 10 weeks of the Behavioral Parent Training (BPT) used in both conditions. The psychoeducation module consists of 6 weekly 2.5-hour sessions, daily homework that includes monitoring progress on goals identified at the end of each session, and a workbook for parents of children with special needs that provides parents with information regarding their child's development, disability, and associated considerations. Each of the 6 weekly sessions includes a general topic for discussion. These include preparing for IEP meetings, navigating the regional center and developmental service agencies, communicating with teachers, advocacy, sibling issues, and community resources.
Study: NCT02880800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine as IVPCA
Description: Morphine as IVPCA: Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of morphine as below:~Morphine bolus 1mg with a lockout interval of 5 minutes, no background infusion and maximum 30 mg in 4 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone as IVPCA
Description: Hydromorphone as IVPCA: Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of Hydromorphone as below:~Hydromorphone bolus 0.2 mg with a lockout interval of 5 minutes and a maximum dose of 6 mg in 4 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: IV opioids: Morphine 2 to 5 mg every 1h PRN (max. 20 mg/4h)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Hydromorphone 0.5 - 1 mg every 1h PRN (max. 4 mg/4h)
Study: NCT00575575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavior therapy
Description: cognitive behavior therapy once a week
Study: NCT03771976

Intervention type: PROCEDURE
Intervention: Cesarean section
Description: Risk of cesarean section between the cohorts

Intervention type: PROCEDURE
Intervention: Cesarean section
Description: Risk of cesarean section between the cohorts

Intervention type: PROCEDURE
Intervention: No cesarean section
Description: Vaginal birth rate between the cohorts

Intervention type: PROCEDURE
Intervention: No cesarean section
Description: Vaginal birth rate between the cohorts
Study: NCT00381966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robotic placement device
Description: this device is a robotic arm that utilizes a template as a guidance system to precisely inplant radioactive brachytherapy seeds directly to the prostate.
Study: NCT04253522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Rehabilitation program in standard ergotherapy and cognitive training with Covirtua Software and Transcranial random noise stimulation
Study: NCT01808209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: filcon II 3
Description: Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
Study: NCT04360421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Patient's undergoing major extremity amputation and enrolled in the study as part of the experimental arm will, during their amputation operation, receive liposomal bupivicaine per recommended manufacturing dosing and administration in a field block for long-acting local anesthesia.
Study: NCT01106872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid
Study: NCT03273387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Description: The participant will received trimetazidine 35 mg bid for 3 months on top of their regular PAH specific therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The participant will received placebo oral capsule bid for 3 months on top of their regular PAH specific therapy.
Study: NCT04086706

Intervention type: PROCEDURE
Intervention: Retroflexion in the Right Colon
Description: Prospective evaluation of an every day technique (retroflexion) used in our department for many years. The protocol of ascending colon examination encompassed 2 phases: A first phase (1) divided in Forward view (1a) videlicet insertion from the right flexure to the caecum followed by a second forward view (1b) namely withdrawal till the right flexure and reinsertion to the caecum maintaining the endoscope straight and a second phase (2, Retroflexion) with U-turn of the colonoscope in the caecum till the right flexure and then redressing to the forward view and reinsertion to the caecum.
Study: NCT01063179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib, Melphalan, Prednisone, Thalidomide
Description: Induction therapy:~9 courses with weekly VELCADE (4 doses) in combination with oral Melphalan 9 mg/m2,oral Prednisone 60 mg/m2 once daily on Days 1 to 4 of each course and Thalidomide 50 mg/day continuously. The dose of VELCADE is 1.3 mg/m2 administered as a bolus IV injection, on days 1, 8, 15, 22.~Maintenance therapy:~Thalidomide 50 mg/day continuously in combination with VELCADE 1.3 mg or maximum dose tolerated/m2/2 weeks. The maintenance will be initiated at the end of the 9th course and will be stopped after progression. The median expected duration of the maintenance treatment is approximately 2 years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib, Melphalan, Prednisone
Description: Induction therapy: 9 courses with weekly VELCADE(4 doses) in combination with oral Melphalan 9 mg/m2 and oral Prednisone 60 mg/m2 once daily on Days 1 to 4 of each course. No maintenance therapy is scheduled
Study: NCT01573520

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring of drug adherence
Description: In the IC group, biological and drug adherence results are shown and discussed through a nephrologists leaded semi-structured motivation interviews at interval of 2 months.
Study: NCT02352506

Intervention type: OTHER
Intervention: Blood draw for measurement of MIF
Description: Observational study, no intervention

Intervention type: OTHER
Intervention: Blood draw for measurement of MIF
Description: Observational study, no intervention
Study: NCT01564758

Intervention type: DRUG
Intervention: Linezolid
Description: 1. Vancomycin-resistant, E. faecium, including concurrent bacteremia: Linezolid for 600mg (IV or oral) every 12 hours for 14-28 days~2. Nosocomial infection, cSSTI: Linezolid for 600mg (IV or oral) every 12 hours for 10-14 days~3. Uncomplicated SSTI: Linezolid for 400mg oral every 12 hours for 10-14 days
Study: NCT00854009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI-489

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo